证券代码：603880 证券简称：南卫股份 公告编号：2026-010 姓名 离任职务 离任 时间 原定任 期到期 日 离任原因 是否继 续在上 市公司 及其控 股子公 司任职 具体职 务（如 适用） 是否 存在 未履 行完 毕的 公开 承诺 许晓 董事、薪酬 与考核委 员会委员、 提名委员 会委员、财 务负责人 2026 年3月 30 日 2028 年 12月24 日 个人职业 发展规划 调整及薪 资不及预 期 否 不适用 否 （一）提前离任的基本情况 江苏南方卫材医药股份有限公司 关于董事兼财务负责人离任 暨指定总经理代行财务负责人职责的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事离任情况 江苏南方卫材医药股份有限公司（以下简称"公司"）于近日收到许晓先生 递交的书面辞职报告，因个人职业发展规划调整及薪资不及预期，许晓先生申请 辞去公司第五届董事会董事、董事会薪酬与考核委员会委员、提名委员会委员及 财务负责人职务，辞职后不再担任公司任何职务。 （二）离任对公司的影响 1 特此公告。 江苏南方卫材医药股份有 ...

证券代码：603880 证券简称：南卫股份 公告编号：2026-009 江苏南方卫材医药股份有限公司 第五届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 江苏南方卫材医药股份有限公司（以下简称"公司"）第五届董事会第三次会 议于 2026 年 3 月 30 日在公司会议室举行，本次会议采取现场表决与通讯表决结 合的方式召开。会议由董事长何凌峰先生主持，本次会议应参加董事 6 名，实际 参加董事 6 名，参会董事同意豁免会议通知时间要求。本次会议的通知、召开及 审议程序符合《公司法》、《证券法》等法律法规及《公司章程》的有关规定，所 作决议合法有效。 二、董事会会议审议情况 2、审议通过《关于调整公司第五届董事会专门委员会组成人员的议案》 公司于 2026 年 3 月 30 日收到许晓先生递交的书面辞职报告，因个人职业发 展规划调整及薪资不及预期，许晓先生申请辞去公司第五届董事会董事、董事会 薪酬与考核委员会委员、提名委员会委员及财务负责人职务，辞职后，许晓先生 将不再担任公司 ...

Core Viewpoint - The announcement from Nanwei Co., Ltd. indicates significant share pledges by its controlling shareholder, Li Ping, which may impact the company's financial stability and investor sentiment [2] Group 1: Share Pledge Details - On February 9, Li Ping released a pledge of 2,000,000 shares and simultaneously pledged the same amount again on the same day [2] - The total shares pledged by Li Ping amount to 92.4 million, representing 77.75% of his holdings and 31.97% of the company's total share capital [2]

江苏南方卫材医药股份有限公司关于 控股股东部分股份解除质押及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至本公告披露日，江苏南方卫材医药股份有限公司（以下简称"公司"） 控股股东李平先生持有公司股份 118,841,048 股，占公司总股本的 41.12%。公 司控股股东李平先生及一致行动人李永平先生、李永中先生合计持有公司股份 136,560,415 股，占公司总股本的 47.25%。本次部分股份解除质押及再质押后， 李平先生累计质押公司股份 92,400,000 股，占其持有公司股份总数的 77.75%， 占公司总股本的 31.97%，李平先生及其一致行动人李永平先生、李永中先生累 计质押公司股份 102,039,338 股，占其合计持有公司股份总数的 74.72%，占公 司总股本的 35.30%。 公司于近日接到公司控股股东李平先生通知，获悉其所持部分公司股份办理 解除质押及再质押业务，具体事项如下： 一、上市公司股份解除质押 | 股东名称 | 李平 | | --- | --- ...

Core Viewpoint - Jiangsu Nanfang Weicai Pharmaceutical Co., Ltd. announced significant shareholding and pledge details of its controlling shareholder, Mr. Li Ping, indicating a high level of pledged shares which may impact investor sentiment and stock performance [1] Shareholding Summary - Mr. Li Ping holds approximately 119 million shares, accounting for 41.12% of the total share capital of the company [1] - Mr. Li Ping and his concerted actors, Mr. Li Yongping and Mr. Li Yongzhong, collectively hold about 137 million shares, representing 47.25% of the total share capital [1] Pledge Details - After the partial release and re-pledge of shares, Mr. Li Ping has pledged a total of 92.4 million shares, which is 77.75% of his total shareholding and 31.97% of the company's total share capital [1] - The total shares pledged by Mr. Li Ping and his concerted actors amount to approximately 102 million shares, which is 74.72% of their combined holdings and 35.3% of the total share capital [1]

Group 1 - The core viewpoint of the news is that Nanwei Co., Ltd. (603880) expects a net profit loss of 80 million yuan for the year 2025, which is an improvement compared to a loss of 191 million yuan in the previous year, primarily due to the market environment affecting its subsidiary Anhui Nanwei Medical's nitrile glove business, which has not fully released its production capacity [1] - For the first three quarters of 2025, the company reported revenue of 447 million yuan, a year-on-year decrease of 1.7%, and a net profit loss of 24.93 million yuan, with a debt ratio of 73.87% [1] - In the third quarter alone, the company achieved revenue of 141 million yuan, with a year-on-year increase in net profit loss of 16.59%, indicating ongoing pressure on overall profitability [1] Group 2 - The stock price of Nanwei Co., Ltd. has shown a volatile upward trend in the past week, closing at 6.79 yuan on February 10, 2026, with a single-day increase of 0.15% and a cumulative increase of 3.51% over the past five days [2] - On February 10, 2026, the main capital outflow was 6.0254 million yuan, accounting for 17.19% of the transaction volume, while on February 9, 2026, the main capital outflow was 84,600 yuan with a transaction volume of 16.1547 million yuan [2] - Technically, the stock price is approaching the upper Bollinger Band resistance level of 6.81 yuan, with short-term moving averages showing a bullish arrangement, although the MACD momentum is weak [2] Group 3 - According to the analysis from Xiangshang Artificial Intelligence Laboratory on February 10, 2026, Nanwei Co., Ltd. has a current price-to-book ratio of 7.51, which is significantly higher than the industry average, indicating a valuation premium, and there are concerns regarding profit quality with a net profit margin of -5.55% [3] - The report highlights the need to be cautious of high debt and cash flow volatility risks, while the narrowing of profit losses is seen as a positive signal, though the sustainability of profit improvement requires observation of subsequent quarterly data [3]

Market Overview - The medical device sector experienced a decline of 1.98% on February 2, with Hai Li Biological leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Top Performers - Mai Pu Medical (301033) saw a closing price of 73.70, with an increase of 8.35% and a trading volume of 31,100 shares, totaling 223 million yuan [1] - Nanwei Co., Ltd. (603880) closed at 6.63, up 5.41%, with a trading volume of 191,200 shares, amounting to 126 million yuan [1] - Gongdong Medical (605369) closed at 19.46, up 2.91%, with a trading volume of 44,800 shares, totaling 86.97 million yuan [1] Underperformers - Hai Li Biological (603718) closed at 5.84, down 10.02%, with a trading volume of 84,500 shares, totaling 49.32 million yuan [2] - Yuanmei Medical (002950) closed at 10.46, down 9.52%, with a trading volume of 255,000 shares, amounting to 269 million yuan [2] - Yikang Technology (688301) closed at 111.34, down 5.92%, with a trading volume of 44,200 shares, totaling 503 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 533 million yuan from institutional investors, while retail investors experienced a net inflow of 174 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Sino Medical (688108) had a net inflow of 46.28 million yuan from institutional investors, while retail investors saw a net outflow of 58.30 million yuan [3] - Mai Pu Medical (301033) experienced a net inflow of 29.68 million yuan from institutional investors, with a net outflow of 34.84 million yuan from retail investors [3] - Gongdong Medical (605369) had a net inflow of 13.18 million yuan from institutional investors, while retail investors faced a net outflow of 9.00 million yuan [3]

Group 1 - The company, Nanwei Co., Ltd. (603880.SH), announced that it expects to report a net profit attributable to shareholders of the parent company of -80 million yuan for the year 2025, indicating a projected loss [1]

Core Viewpoint - Nanwei Co., Ltd. (603880.SH) is expected to report a net loss attributable to shareholders of the parent company amounting to 80 million yuan for the fiscal year 2025, indicating a challenging financial outlook for the company [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be approximately -82 million yuan for the fiscal year 2025 [1]

Financial Performance - The company expects a net loss of 80 million yuan for the fiscal year 2025, with a net profit attributable to the parent company after deducting non-recurring gains and losses projected at -82 million yuan [3]. - In the same period last year, the total profit was -200.86 million yuan, with a net profit attributable to the parent company of -190.67 million yuan, and a net profit after deducting non-recurring gains and losses of -187.73 million yuan [4]. - The earnings per share for the previous year was -0.66 yuan [4]. Operational Challenges - The poor performance in 2025 is primarily due to the underutilization of production capacity in the subsidiary's nitrile glove business, which was adversely affected by the industry market environment [7]. Earnings Forecast - The company emphasizes that the earnings forecast is based on preliminary calculations by the finance department and has not been audited by certified public accountants [9]. - There are no significant uncertainties affecting the accuracy of this earnings forecast as of the announcement date [8]. - The company advises investors to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial data [9].